[1]黄伟东　廖 佳　郑玲玲　袁腾骅 吴 栓.基于网络药理学探究四神煎治疗糖尿病周围神经病变的分子机制[J].大众科技,2023,25(1):92-97.
　Exploration on Molecular Mechanism of Sishenjian in Treating Diabetic Peripheral Neuropathy Based on Network Pharmacology[J].Popular Science & Technology,2023,25(1):92-97.
点击复制

基于网络药理学探究四神煎治疗糖尿病 周围神经病变的分子机制()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
25
期数:
2023年1
页码:
92-97
栏目:
医药与卫生
出版日期:
2023-01-20

文章信息/Info

Title:
Exploration on Molecular Mechanism of Sishenjian in Treating Diabetic Peripheral Neuropathy Based on Network Pharmacology
作者:
黄伟东1; 4　廖 佳2　郑玲玲3　袁腾骅3 吴 栓4
（1.广州中医药大学，广东 佛山 528200； 2.广州中医药大学针灸康复临床医学院，广东 广州 510006； 3.暨南大学研究生院，广东 广州 510632；4.广东省中西医结合医院，广东 佛山 528200）
关键词:
四神煎; 糖尿病周围神经病变; 网络药理学; 分子对接; 靶点预测
Keywords:
Sishenjian diabetic peripheral neuropathy network pharmacology molecular docking target prediction
文献标志码:
A
摘要:
目的：基于网络药理学及分子对接技术，探究四神煎治疗糖尿病周围神经病变（Diabetic peripheral neuropathy，DNP）的药理分子机制，为经典方剂临床应用提供初步的现代理论依据。方法：通过Batman-TCM数据库（http://bionet.ncpsb. org/batman-tcm/）获取黄芪、石斛、牛膝、远志、金银花五味中药的主要化学成分及靶点信息；利用String 11.0数据库（https://www.string-db.org/）进行蛋白质相互作用分析，构建PPI网络并进行可视化分析，预测其中发挥作用的主要蛋白靶点。在Metascape数据库进一步分析核心靶点参与的生物过程及通路，采用CytoScape 3.8.0软件构建“四神煎成分-核心靶点-通路”关系网，分析其中主要发挥作用的成分及关键靶标，最后运用AutoDockTools-1.5.6进行分子对接，对接结果用PyMOL显示。结果：得到四神煎治疗DNP的活性成分79个，对应靶点456个，交集核心靶点113个，预测四神煎治疗DNP的主要活性成分为茉莉酮，核心基因ALB、TNF、PTGS2、CREB1、CAT、PPARG、NOS3、ESR1、PTGS1、AR等。分子对接中活性成分与目标蛋白的结合能均低于-1.0 kcal/mol，大部分靶点与成分的结合活性较好。生物富集分析中，大部分通路与DNP密切相关，其中胃酸分泌通路、Apelin信号通路、对氧化应激的反应、抗氧化、氧结合等富集通路为四神煎调治DNP的关键代谢通路。结论：研究发现四神煎能通过多成分、多靶点、多通路治疗DNP患者，主要活性成分与目标蛋白的对接结果较好，为四神煎治疗DNP进一步提供现代药理分子机制，为临床上运用四神煎治疗DNP提供初步的理论基础。
Abstract:
Objective: Based on network pharmacology and molecular docking technology, to explore the pharmacological mechanism and molecular of Sishenjian in treating diabetic peripheral neuropathy (DPN), and to provide preliminary modern theoretical basis for the clinical application of classical prescriptions. Methods: Through Batman-TCM database（http://bionet.ncpsb.org/batman-tcm/）to obtain the main chemical components and target information of five traditional Chinese medicines: Astragalus, Dendrobium, Achyranthes bidentata, Polygala tenuifolia and honeysuckle the protein interaction was analyzed by String 11.0 database (https://www.string-db.org/). PPI network was constructed and visual analysis was carried out to predict the main protein targets at play. The biological processes and pathways involved by the core targets were further analyzed in the Metascape database, and the relationship network of "Sishenjin components-core targets-pathways" was constructed by CytoScape 3.8.0 software, and the main components and key targets were analyzed. Finally, AutoDockTools-1.5.6 was used for molecular docking, and the docking results were displayed by Pymol. Results: 79 active components of Sishenjian in the treatment of DNP, 456 corresponding targets and 113core targets were obtained. It was predicted that the main active components of Sishenjian in the treatment of DNP were jasmonone and the core genes ALB, TNF, PTGS2, CREB1, CAT PPARG, NOS3, ESR1, PTGS1, AR and so on. In molecular docking, the binding energy of active components and the target proteins were all lower than -1.0 kcal/mol, and most of the targets had good binding activity with the components. In bioaccumulation analysis, most of the pathways were closely related to DNP, among which gastric acid secretion pathway, Apelin signal pathway, reaction to oxidative stress, antioxidant, oxygen binding and other enrichment pathways were the key metabolic pathways of Sishenjian in the treatment of DNP. Conclusion: This study found that Sishenjian could treat patients with DNP through multi-component, multi-target and multi-pathway treatment. The docking results between the main active components and the target protein were good, which further provided a modern pharmacological and molecular mechanism for Sishenjian in the treatment of DNP and provided the preliminary theoretical basis for the clinical application of Sishenjian in the treatment of DNP.

参考文献/References:

[1]　金合. 《验方新编》四神煎临床应用进展[J]. 中国中医药信息杂志，2013，20(5): 110-112. [2] 方朝晖，吴以岭，赵进东. 糖尿病周围神经病变中医临床诊疗指南(2016年版)[J]. 中医杂志，2017，58(7): 625-630. [3] 程群才，吕全梅. 四神煎加味治疗糖尿病周围神经病变35例[J]. 医学理论与实践，2005，18(5): 555-556. [4] 刘嵘，张芙蓉，张汉平. 穴位埋线合加味四神煎治疗糖尿病周围神经病变30例[C]. 国际特种针法疗法演示暨学术研讨会，2013. [5] 安学冬，金德，段丽云，等. 仝小林论治痛性糖尿病周围神经病变[J]. 吉林中医药，2021，41(1): 31-34. [6] 孟凡翠，汤立达. 中药网络药理学研究中存在的问题与发展展望[J]. 中草药，2020，51(8): 2232-2237. [7] 陈士光，赖璐华，邓珊珊，等. 2型糖尿病周围神经病变患者IGF-1水平变化及其临床意义[J]. 现代医院，2021，21(5): 807-809. [8] 吕翠岩. 糖痹康干预糖尿病周围神经病变临床及作用机制研究[D]. 北京: 北京中医药大学，2014. [9] SHEHLA A, FAZAL S, MUHAMMAD S et al. 6-Methoxyflavanone abates cisplatin-induced neuropathic pain apropos anti-inflammatory mechanisms: A behavioral and molecular simulation study[J]. European Journal of Pharmacology, 2020, 872: 172972. [10] 李雪芹. CAT及其基因多态性与2型糖尿病周围神经病变的关系[D]. 昆明: 昆明医学院，2011. [11] BROWNLEE M. The pathobiology of diabetic complications a unifying mechanism [J]. Diabetes, 2005, 54(6): 1615-1625. [12] 彭哲，田绍文，谢明. Apelin与2型糖尿病相关性研究进展[J]. 中国动脉硬化杂志，2014，22(10): 1077-1080. [13] DRAY C, KNAUF C, DAVIAUD D, et al. Apelin stimulates?lucose utilization in normal and obese insulin-resistant mice[J]. Cell Metabolism, 2008, 8(5): 437445. [14] 杨丹. 基于氧化应激探讨中药筋脉通对糖尿病周围神经损伤后修复再生的作用机制[D]. 北京: 北京协和医学院，2015.

相似文献/References:

[1]罗 幸 邓小敏 麦小丽 陈方飞 田 瑛 苏 冬.补阳还五汤化裁治疗糖尿病周围神经病变研究进展[J].大众科技,2020,22(09):67.
　Research Progress of Buyang Huanwu Decoction in Treating Diabetic Peripheral Neuropathy[J].Popular Science & Technology,2020,22(1):67.

备注/Memo

备注/Memo:
【收稿日期】2022-10-27 【基金项目】广东省中医药局科研项目“基于数据挖掘技术探究‘三脏一体’辨证模式治疗KOA的组方规律及核心处方研究”（20202036）。 【作者简介】黄伟东（1995－），男，广东汕头人，广州中医药大学在读硕士研究生，研究方向为中西医结合治疗痹证。 【通信作者】吴栓，男，广东省中西医结合医院脊柱骨科主任，硕士研究生导师，研究方向为中西医结合治疗脊柱相关疾病。
更新日期/Last Update: 2023-03-30